150 related articles for article (PubMed ID: 37902122)
41. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART).
Mata N; Alonso R; Badimón L; Padró T; Fuentes F; Muñiz O; Perez-Jiménez F; López-Miranda J; Díaz JL; Vidal JI; Barba A; Piedecausa M; Sanchez JF; Irigoyen L; Guallar E; Ordovas JM; Mata P
Lipids Health Dis; 2011 Jun; 10():94. PubMed ID: 21663647
[TBL] [Abstract][Full Text] [Related]
42. Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Lozano P; Henrikson NB; Dunn J; Morrison CC; Nguyen M; Blasi PR; Anderson ML; Whitlock EP
JAMA; 2016 Aug; 316(6):645-55. PubMed ID: 27532919
[TBL] [Abstract][Full Text] [Related]
43. Familial hypercholesterolemia in children and the importance of early treatment.
van den Bosch SE; Hutten BA; Corpeleijn WE; Kusters DM
Curr Opin Lipidol; 2024 Jun; 35(3):126-132. PubMed ID: 38363694
[TBL] [Abstract][Full Text] [Related]
44. Efficiency and problems of statin therapy in patients with heterozygous familial hypercholesterolemia.
Korneva V; Kuznetsova T; Julius U
Atheroscler Suppl; 2019 Dec; 40():79-87. PubMed ID: 31818452
[TBL] [Abstract][Full Text] [Related]
45. How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?
Kataoka Y; Funabashi S; Doi T; Harada-Shiba M
J Atheroscler Thromb; 2022 Jun; 29(6):795-807. PubMed ID: 35022364
[TBL] [Abstract][Full Text] [Related]
46. The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia.
Pang J; Chan DC; Watts GF
Curr Atheroscler Rep; 2020 Sep; 22(11):64. PubMed ID: 32870376
[TBL] [Abstract][Full Text] [Related]
47. Cardiovascular disease onset in old people with severe hypercholesterolemia.
Coutinho ER; Miname MH; Rocha VZ; Bittencourt MS; Jannes CE; Krieger JE; Pereira AC; Santos RD
Atherosclerosis; 2023 Jan; 365():9-14. PubMed ID: 36646017
[TBL] [Abstract][Full Text] [Related]
48. Sex differences in the perception of cardiovascular risk in familial hypercholesterolemia.
Alshibani B; Iatan I; Guerin A; Ruel I; Cermakova L; Ramanakumar AV; Pilote L; Coutinho T; Brunham LR; Genest J
J Clin Lipidol; 2024; 18(1):e97-e104. PubMed ID: 37926591
[TBL] [Abstract][Full Text] [Related]
49. Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol.
Zhang Y; Dron JS; Bellows BK; Khera AV; Liu J; Balte PP; Oelsner EC; Amr SS; Lebo MS; Nagy A; Peloso GM; Natarajan P; Rotter JI; Willer C; Boerwinkle E; Ballantyne CM; Lutsey PL; Fornage M; Lloyd-Jones DM; Hou L; Psaty BM; Bis JC; Floyd JS; Vasan RS; Heard-Costa NL; Carson AP; Hall ME; Rich SS; Guo X; Kazi DS; de Ferranti SD; Moran AE
JAMA Cardiol; 2024 Mar; 9(3):263-271. PubMed ID: 38294787
[TBL] [Abstract][Full Text] [Related]
50. A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.
McCormick D; Bhatt DL; Bays HE; Taub PR; Caldwell KA; Guerin CK; Steinhoff J; Ahmad Z; Singh R; Moreo K; Carter J; Heggen CL; Sapir T
J Manag Care Spec Pharm; 2020 Dec; 26(12):1517-1528. PubMed ID: 33251993
[No Abstract] [Full Text] [Related]
51. The effects of 3-year statin therapy and the achievement of LDL cholesterol target values in familial hypercholesterolemia patients: An experience from Serbia.
Lalić K; Rajković N; Popović L; Lukač SS; Stošić L; Rasulić I; Lalić NM
Atherosclerosis; 2018 Oct; 277():298-303. PubMed ID: 30270062
[TBL] [Abstract][Full Text] [Related]
52. Increased FH-Risk-Score and Diabetes Are Cardiovascular Risk Equivalents in Heterozygous Familial Hypercholesterolemia.
Paquette M; Cariou B; Bernard S; Hegele RA; Gallo A; Genest J; Trinder M; Brunham LR; Béliard S; Baass A
Arterioscler Thromb Vasc Biol; 2024 Feb; 44(2):505-512. PubMed ID: 38031840
[TBL] [Abstract][Full Text] [Related]
53. The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients.
Davidson M
Clin Ther; 2013 Aug; 35(8):1247-52. PubMed ID: 23916045
[TBL] [Abstract][Full Text] [Related]
54. Substantially Elevated Atherosclerotic Risks in Japanese Severe Familial Hypercholesterolemia Defined by the International Atherosclerosis Society.
Funabashi S; Kataoka Y; Hori M; Ogura M; Nakaoku Y; Nishimura K; Doi T; Nishikawa R; Tsuda K; Noguchi T; Harada-Shiba M
JACC Asia; 2021 Sep; 1(2):245-255. PubMed ID: 36338164
[TBL] [Abstract][Full Text] [Related]
55. Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia.
Watts GF; Sullivan DR; Hare DL; Kostner KM; Horton AE; Bell DA; Brett T; Trent RJ; Poplawski NK; Martin AC; Srinivasan S; Justo RN; Chow CK; Pang J;
Heart Lung Circ; 2021 Mar; 30(3):324-349. PubMed ID: 33309206
[TBL] [Abstract][Full Text] [Related]
56. Guidelines for the management of familial hypercholesterolemia.
Harada-Shiba M; Arai H; Oikawa S; Ohta T; Okada T; Okamura T; Nohara A; Bujo H; Yokote K; Wakatsuki A; Ishibashi S; Yamashita S
J Atheroscler Thromb; 2012; 19(12):1043-60. PubMed ID: 23095242
[TBL] [Abstract][Full Text] [Related]
57. Identification and characterization of severe familial hypercholesterolemia in patients presenting for cardiac catheterization.
Zafrir B; Shapira C; Lavie G; Halon DA; Flugelman MY
J Clin Lipidol; 2016; 10(6):1338-1343. PubMed ID: 27919350
[TBL] [Abstract][Full Text] [Related]
58. The development and first results of a health-related outcomes set in familial hypercholesterolemia (FH) patients: Knowledge is health.
Mulder JWCM; Galema-Boers AMH; de Jong-Verweij LM; Hazelzet JA; Roeters van Lennep JE
Atherosclerosis; 2020 Jan; 293():11-17. PubMed ID: 31821958
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
[TBL] [Abstract][Full Text] [Related]
60. LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia.
Bogsrud MP; Græsdal A; Johansen D; Langslet G; Hovland A; Arnesen KE; Mundal LJ; Retterstøl K; Wium C; Holven KB
J Clin Lipidol; 2019; 13(2):279-286. PubMed ID: 30910667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
